Therapeutic Inhibition of the SRC-Kinase HCK Facilitates T Cell Tumor Infiltration and Improves Response to Immunotherapy

The authors demonstrated that genetic ablation or therapeutic inhibition of the myeloid-specific hematopoietic cell kinase enabled activity of antagonistic anti–programmed cell death protein 1, anti-CTLA4, or agonistic anti-CD40 immunotherapies in otherwise refractory tumors and augments response in treatment-susceptible tumors.